David Price, Professor of Primary Care Respiratory Medicine, University of Aberdeen, UK
Research Team:Status: Planned Study, Seeking Funding
A historical observational comparison of benefits and risks in patients with obstructive lung disease managed with extra-fine and fine particle inhaled corticosteroids in UK primary care.
The primary objective of the study is to compare whether patients prescribed EF ICS are associated with a slower diabetic progression than F ICS in asthma.
The secondary objective of the study is to compare the:
- Annual rate or incidence of ICS risks and benefits in patients with OLD managed on EF vs F ICS and on EF vs F ICS/LABA;
- Time to first event or rate of ICS risks and benefits as appropriate in patients with OLD managed on EF vs F ICS and on EF vs F ICS/LABA;
- Relationship between ICS exposure (average daily dose or change in average daily dose) and ICS risks and benefits will also be explored.
Documents and Publications